Bifogade filer
PDF
Kalender
| Est. tid* | ||
| 2026-05-11 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-27 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-21 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-29 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-24 | - | Årsstämma |
| 2025-05-19 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2025-05-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-08 | - | Extra Bolagsstämma 2025 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-20 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-04 | - | Extra Bolagsstämma 2024 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2023-05-12 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-08 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2022-05-23 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-06 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-22 | - | Extra Bolagsstämma 2021 |
| 2021-06-09 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2021-06-08 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | Extra Bolagsstämma 2020 |
| 2020-05-13 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2020-05-12 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-22 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-12-13 | - | Extra Bolagsstämma 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
| 2018-05-23 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-28 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Inhalation Sciences Sweden AB ("ISAB") has received a major Inhalation Research Services (IRS) order from a large global pharmaceutical company with commercial presence in more than 100 countries, including the US and Europe. The order value amounts to a total of EUR 224,555, corresponding to approximately SEK 2.45 million.
The assignment covers advanced in vitro dissolution testing using ISAB's proprietary DissolvIt® technology, in which several different inhalation formulations will be evaluated and compared to generate high-precision data that support the customer's continued development and optimization of its inhaled drug candidates.
"We are very pleased to receive this substantial IRS order from a leading global pharmaceutical company. This project is an important validation of DissolvIt® as a high-precision tool for comparing complex inhalation formulations in the preclinical phase, and the size and structure of the order, involving multiple formulations and study phases, confirms the growing demand for sophisticated dissolution testing in inhalation drug development", says Manoush Masarrat, CEO of Inhalation Sciences.
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.
This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on December 22, 2025 at 08:30.